Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04770337
Other study ID # NE001
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 25, 2021
Est. completion date December 2024

Study information

Verified date June 2024
Source Neuroelectrics Corporation
Contact Julia Casanovas, Engineer
Phone 34 93 254 03 66
Email julia.casanovas@neuroelectrics.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multiple site, randomized, double blinded parallel-group controlled study. The purpose of this study is to evaluate efficacy, safety, and tolerability of repeated, daily sessions with the STARSTIM device, which delivers transcranial cathodal direct current stimulation (tDCS). Subjects will be treated with STARTSTIM or sham device for 10 sessions over a 2-week period. The subjects will be followed for an additional 10 weeks post treatment. Quality of Life questionnaires and adverse events will be collected and evaluated.


Description:

Study design is an evaluation of the STARSTIM device (tDCS) in subjects over 9 years of age, diagnosed with epilepsy with focal seizures with or without focal to bilateral tonic clonic seizures. Seizure diaries will be collected for 12 weeks to establish a rate of seizure for each subject prior to treatment. Subjects will be randomized in a 1:1 ratio to receive an active STARSTIM treatment or a sham treatment. Neither the study investigator nor subject shall be notified of the treatment assignment. Treatment will be done daily at the investigator's site for 10 days. A Seizure Diary will be maintained through the course of the treatment and the follow up period. Subjects will have 3 follow up visits to evaluate their seizure rate, adverse events, medications and quality of life. A Data Safety Monitoring Board will be utilized to evaluate safety events through study milestones. Seizure frequency rates pre, during and post treatment will be evaluated for both the active and sham treatment arms.


Recruitment information / eligibility

Status Recruiting
Enrollment 190
Est. completion date December 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 9 Years and older
Eligibility Inclusion Criteria: 1. 9 years old or older 2. Diagnosis of epilepsy with focal seizures with or without focal to bilateral tonic clonic seizures (International League Against Epilepsy classification). Diagnosis established by both clinical history and an EEG consistent with focal seizures. Note: A normal interictal EEG is consistent with focal seizures, if other data is adequate to provide localization. 3. Epilepsy is refractory to treatment, defined as: failure to achieve adequate seizure control despite demonstrated compliance, according to medical records, on at least two (2) FDA-approved ASDs at a daily dose considered therapeutic for the patient's demographic according to package labeling, within approximately the last 3 years. 4. Seizure frequency =3 per month, over the past year. 5. Currently on =1 ASDs with no changes in antiepileptic drug doses in the 3 weeks prior to baseline visit in the study and no planned dose changes during the trial. Changes after baseline visit are permitted only if clinically necessary. 6. An MRI scan of the brain using 1.5 Tesla magnet, or greater, with T1, T2, and FLAIR sequences, performed within past 3 years and more recently than any craniotomy or skull burr hole procedure. 7. Seizure focus that allows design of an appropriate stimulation montage. Note: Seizure focus can be identified within a lobe, or 2 adjacent lobes. Identification of the border of the seizure focus can be approximate (+/- 2 gyri). 8. Available seizure history and supporting data 9. All female study subjects of child-bearing age are required to have a pregnancy test. Additionally, all females of childbearing potential will be required to use an effective method of birth control (defined as having a documented failure rate of <=1%; for women using enzyme-inducing ASDs hormonal contraceptives will not be considered as effective). 10. Written informed consent obtained from study subject or subject's legal representative and ability for study subject to comply with the requirements of the study. 11. Assent from pediatric subjects when appropriate. Exclusion Criteria: 1. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the subject or the integrity of the data. 2. Evidence for more than one seizure focus. (NOTE: For this study, a seizure focus is defined as a cortical region confined to one hemisphere and either one lobe or on a junction of two adjacent lobes from which seizures arise , as documented by scalp or intracranial EEG, that is either supported or not refuted by MRI, and either supported or not refuted by clinical semiology). If the interictal EEG is normal, a seizure focus may be identified by the combination of structural findings on MRI and clinical signs/symptoms associated with the subject's seizures. 3. Seizure focus is one of: interhemispheric, cingulate, or orbitofrontal 4. Seizure focus is hemispheric or poorly defined 5. History of psychogenic nonepileptic seizures in past 2 years, or physiologic nonepileptic seizures and non-epileptogenic events, including suspicion for or a significant history of syncope, and any non-epileptic events must be clearly differentiable from subject's focal seizures based on previously recorded video EEG showing distinct clinical and electrographic features of the subject's PNES compared to their epileptic seizures. 6. Seizures of generalized onset 7. Status epilepticus in the last 12 months 8. Presence of any disease, medical condition or physical condition that, in the opinion of the Investigator, may compromise interfere, limit, affect or reduce the subject's ability to complete a study of 24 weeks duration 9. Presence of any disease, medical condition or physical condition that, in the opinion of the Investigator, may adversely impact the safety of the subject or the integrity of the data. 10. Damaged skin on scalp that may interfere with tDCS stimulation. 11. Pregnant or unwilling to practice birth control during participation in the study. 12. Nursing mothers. 13. Any cranial metal implants (excluding ?1 mm thick epicranial titanium skull plates and dental fillings) or medical devices (i.e. cardiac pacemaker, deep brain stimulator, medication infusion pump, cochlear implant). Note: Vagus nerve stimulator (VNS) is allowable if the device is in MR Mode (e.g. switched off) during tDCS stimulation and the VNS device is MR conditional. 14. Previous surgeries opening the skull leaving skull defects capable of allowing the insertion of a cylinder with a radius greater or equal to 5 mm. 15. A history of addiction to, dependence on, abuse of, misuse of, distribution of, or use of any illicit substance.

Study Design


Intervention

Device:
STARSTIM device
Cathodal Transcranial Direct Current Stimulation (tDCS). Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.
Sham Device
Intervention which uses enough currents to generate a sensory feedback similar to that of active stimulation via electrodes on the scalp

Locations

Country Name City State
Belgium Cliniques Universitaires Saint Luc Bruxelles
Belgium Ghent University Hospital Ghent
France Hospices Civils De Lyon Lyon
France CHU de Marseille - Hôpital de la Timone Marseille
Spain Hospital Universitario Albacete Albacete
Spain HM Nou Delfos Barcelona
Spain Hospital Clínic Barcelona
Spain Hospital Del Mar Barcelona
Spain Hospital Sant Joan de Déu Barcelona
Spain Hospital Universitari Vall d'Hebron Barcelona
Spain Hospital Niño Jesús Madrid
Spain Hospital Ruber Internacional Madrid
Spain Hospital Universitario Regional de Málaga Málaga
Spain Centro de Neurología Avanzada Sevilla
United States Johns Hopkins University Baltimore Maryland
United States Sinai Hospital Baltimore Maryland
United States Beth Israel Deconess Medical Center Boston Massachusetts
United States Boston Children's Hospital Comprehensive Epilepsy Center Boston Massachusetts
United States University of Florida Jacksonville Jacksonville Florida
United States Loma Linda University Health Loma Linda California
United States Keck Medicine of USC Los Angeles California
United States Vanderbilt University Medical Center Nashville Tennessee
United States Robert Wood Johnson Medical School (Rutgers) New Brunswick New Jersey
United States Children's Hospital of Orange County Orange California
United States University of Pennsylvania (Penn Epilepsy) Philadelphia Pennsylvania
United States Barrow Neurological Institute, St. Joseph's Hospital & Medical Center Phoenix Arizona
United States Mayo Clinic Rochester Minnesota
United States University of Rochester Rochester New York
United States Washington University Medical Center Saint Louis Missouri
United States University Of Utah Salt Lake City Utah
United States Seattle Children's Hospital, University of Washington Seattle Washington
United States Southern Illinois University School of Medicine Springfield Illinois

Sponsors (1)

Lead Sponsor Collaborator
Neuroelectrics Corporation

Countries where clinical trial is conducted

United States,  Belgium,  France,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary The difference between active treatment and sham treatment in the percentage change from baseline in seizures over the 12 weeks following initiation of treatment.
Secondary The proportion of subjects who are responders (defined as subjects with a 50% or greater reduction in seizure frequency from baseline to week 12 post-treatment
See also
  Status Clinical Trial Phase
Completed NCT04595513 - Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants Phase 1/Phase 2
Completed NCT02909387 - Adapting Project UPLIFT for Blacks in Georgia N/A
Completed NCT05552924 - Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients N/A
Terminated NCT01668654 - Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS Phase 3
Not yet recruiting NCT05068323 - Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients N/A
Completed NCT03994718 - Creative Arts II Study N/A
Recruiting NCT04076449 - Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
Completed NCT00782249 - Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy N/A
Completed NCT03683381 - App-based Intervention for Treating Insomnia Among Patients With Epilepsy N/A
Recruiting NCT05101161 - Neurofeedback Using Implanted Deep Brain Stimulation Electrodes N/A
Active, not recruiting NCT06034353 - Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients N/A
Recruiting NCT05769933 - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Not yet recruiting NCT06408428 - Glioma Intraoperative MicroElectroCorticoGraphy N/A
Not yet recruiting NCT05559060 - Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
Completed NCT02952456 - Phenomenological Approach of Epilepsy in Patients With Epilepsy
Completed NCT02646631 - Behavioral and Educational Tools to Improve Epilepsy Care N/A
Completed NCT02977208 - Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use Phase 4
Recruiting NCT02539134 - TAK-935 Multiple Rising Dose Study in Healthy Participants Phase 1
Completed NCT02491073 - Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL) N/A
Terminated NCT02757547 - Transcranial Magnetic Stimulation for Epilepsy N/A